Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
1. UBX stock dropped 34.8% following study results release. 2. UBX1325 showed visual acuity gains but had mixed results compared to aflibercept. 3. 37% of patients needed supplemental anti-VEGF treatment due to CST increase. 4. Safety profile of UBX1325 remained favorable; full data expected by Q2 2025. 5. Financial position supports operations until Q4 2025 despite stock decline.